论文部分内容阅读
Rochester 医疗中心自1963年3月—1978年3月收治30例副鼻窦恶性肿瘤病人,大多数病人用~(60)Co 放疗,采用1野和2侧野照射,每一个病人均按病变范围设计照射野的形状.某些病例用10—18mev 和~(60)Co 联合放疗得到一个满意的等剂量曲线,上颌窦、鼻窦及筛窦均包括在放射野之内,21例眼眶一半在有效放射剂量之内,9例整个眼球被照射.20例上颌窦癌病例中5例术前放疗,剂量自4950rad/33天—7000rad/50天,10例接受术前或单纯放疗,剂量3400rad/24天—8600rad/43天。5例行根治性放疗,剂量在6000rad/50天—7500rad/73天。9例筛窦癌中3例术前放射剂量在4950～5500rad/5～6周,4例术前放疗剂量在5000rad/42天～7200rad/56天,2例因有远处转移仅行姑息放疗.4/30例无眼眶侵犯均挡眼。4例均长期生存,其中3例视力正常,仅1例12年半以后发生第2、3、5、6对颅神经功能损伤,以致视力下降至失明,手术证明眼血管纤维组织伴广泛玻璃变性,无肿瘤复发.
Rochester Medical Center treated 30 patients with paranasal sinus malignant tumor from March 1963 to March 1978. The majority of patients were treated with 60Co radiation, and 1 field and 2 fields were used. Each patient was designed according to the lesion area. The shape of the irradiation field. In some cases, a satisfactory isodose curve was obtained with 10-18 mev and ~(60)Co combined radiotherapy. The maxillary sinus, paranasal sinuses, and ethmoid sinus were all included in the radiation field. In 21 cases, half of the eyelids were effectively radiated. Within the dose, 9 cases of the entire eye were irradiated. 20 cases of maxillary sinus cancer in 5 cases of preoperative radiotherapy, dose from 4950rad/33 days -7000rad/50 days, 10 cases received preoperative or radiotherapy alone, dose 3400rad/24 days - 8600rad/43 days. Radical radiotherapy was performed in 5 patients. The dose was 6000rad/50 days - 7500rad/73 days. Among 9 cases of ethmoid sinus carcinoma, 3 cases had preoperative radiation doses from 4950 to 5500 rad/5 to 6 weeks, 4 cases had preoperative radiation doses from 5000rad/42 days to 7200rad/56 days, and 2 cases had palliative radiotherapy due to distant metastases. .4/30 cases of eyelid violations were blind. All 4 cases had long-term survival, of which 3 cases had normal vision. Only 1 case occurred 2, 3, 5, and 6 of cranial nerve function impairment after 12 and a half years, resulting in decreased visual acuity to blindness. Operation demonstrated ocular vascular fibrous tissue with extensive glass degeneration. No tumor recurrence.